Takeda Pharmaceutical Co. Ltd. Drops Europe Development of Insomnia Drug

Published: Oct 10, 2011

Takeda Pharmaceutical said on Friday it would discontinue development of insomnia drug ramelteon in Europe, after feedback on development requirements from the region's regulatory body. The drug, available as Rozerem in the United States and Japan, was once seen as a promising source of income for the Japanese firm, but sales never took off as expected because some patients found its effects were not as strong or immediate as desired.

Back to news